Tumor and Stem Cell Biology Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer
Erin D. Giles,E. Wellberg,D. Astling,S. Anderson,A. Thor,S. Jindal,A. Tan,P. Schedin,P. MacLean
Abstract:Obese postmenopausal women have increased risk of breast cancers with poorer clinical outcomes than their lean counterparts. However, the mechanisms underlying these associations are poorly understood. Rodent model studies have recently identified a period of vulnerability for mammary cancer promotion, which emerges during weight gain after the loss of ovarian function (surgical ovariectomy; OVX). Thus, a period of transient weight gain may provide a life cycle–specific opportunity to prevent or treat postmenopausal breast cancer. We hypothesized that a combination of impaired metabolic regulation in obese animals prior to OVX plus an OVX-induced positive energy imbalancemight cooperate to drive tumor growth and progression. To determine if lean and obese rodents differ in theirmetabolic response toOVX-inducedweight gain, andwhether this difference affects later mammary tumor metabolism, we performed a nutrient tracer study during the menopausal window of vulnerability. Lean animals preferentially deposited excess nutrients tomammary and peripheral tissues rather than to the adjacent tumors. Conversely, obese animals deposited excess nutrients into the tumors themselves. Notably, tumors from obese animals also displayed increased expression of the progesterone receptor (PR). Elevated PR expression positively correlated with tumor expression of glycolytic and lipogenic enzymes, glucose uptake, and proliferationmarkers. Treatment with the antidiabetic drugmetformin during ovariectomy-induced weight gain caused tumor regression and downregulation of PR expression in tumors. Clinically, expression array analysis of breast tumors from postmenopausal women revealed that PR expression correlated with a similar pattern of metabolic upregulation, supporting the notion that PRþ tumors have enhanced metabolic capacity after menopause. Our findings have potential explanative power in understanding why obese, postmenopausal women display an increased risk of breast cancer. Cancer Res; 72(24); 6490–501. 2012 AACR. Introduction Obesity increases incidence, progression, and mortality from breast cancer (1), with the adverse effects of obesity primarily observed in postmenopausal woman (1, 2). After menopause, adipose tissue becomes a significant site for the production of estrogens,whichmay lead to tumorpromotion inobesewomen. Supporting this assertion, some studies indicate that circulating estrogens are higher with increasing weight (3) and obesity generally promotes hormone-dependent tumors (4, 5). A recent study has also shown that adipose tissue aromatase activity increases with adiposity (6). Despite this evidence, local levels of estrogens in breast tissue of postmenopausal women were unaffectedbyobesity (7). Furthermore, a decrease inbothbreast cancer risk and mortality was recently reported in postmenopausal women receiving oral estrogens, independent of body mass index (BMI; ref. 8). Thus, while estrogen and obesity clearly interact to influence breast cancer, our understanding of this complex relationship remains incomplete. Obesity is associatedwith impairedwhole bodymetabolism, including a decreased ability to quickly clear and store excess calories during periods of overfeeding (9, 10). Weight gain is very common during menopause, in part, because loss of ovarian estrogen reduces leptin sensitivity in the hypothalamus, thus promoting overfeeding (11). Unless proactive measures are made to replace the loss of ovarian estrogen, restrict energy intake, and/or increase energy expenditure postmenopause, weight gain ensues (12). Calorie restriction and/or weight loss reportedly reduces tumorigenesis and the mitogenic potential of serum (13–16). Conversely, the overfeeding and weight gain associated with menopause is anticipated to create a host environment rich in circulating excess nutrients (particularly glucose and fatty acids), and growth factors [insulin, insulin-like growth factor-I (IGF-I), EGF, and leptin], Authors' Affiliations: Anschutz Health and Wellness Center; Department of Pathology; Division of Endocrinology, Metabolism and Diabetes, and Division of Medical Oncology in the Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/). Corresponding Author: Paul MacLean, University of Colorado Anschutz MedicalCampus, 12800East 19thAvenue, Aurora, CO80045. Phone: 303724-3030; Fax: 303-724-3031; E-mail: Paul.MacLean@ucdenver.edu doi: 10.1158/0008-5472.CAN-12-1653 2012 American Association for Cancer Research. Cancer Research Cancer Res; 72(24) December 15, 2012 6490 all of which have been shown to promote tumor cell growth (17). This tumor-promoting humoral milieu is predicted to be exacerbated in obese patients because of the preexisting impairment in energy metabolism. We have studied the impact of premenopausal obesity on postmenopausal breast cancer outcomes in an experimental paradigm that mergesmodels of obesity (10, 18, 19), mammary tumorigenesis (20, 21), and menopause (ovariectomy; OVX; ref. 22). In that study, an effect of premenopausal obesity on tumor promotion emerged during the period of rapid, OVXinduced weight gain (23). In the present study, we used this model and found that premenopausal obesity status and menopause-induced overfeeding influence mammary tumor glucose and fatty acid metabolism, and identified a putative novel role for progesterone receptor (PR) in mediating these effects. Materials and Methods Animals Female Wistar rats (100–125 g; 5 weeks) purchased from Charles River Laboratories were individually housed in metabolic caging at 22 to 24 C and 12:12-hour light-dark cycle with free access to water. To induce obesity, rats were maintained on purified high-fat diet (HF; 46% kcal fat; Research Diets, RD#D12344). All animal procedures were approved by the Institutional Animal Care and Use Committee. Obesity and postmenopausal breast cancer model Rats were injected with 1-methyl-1-nitrosourea (MNU, 50 mg/kg) at 52 1 days of age to induce mammary tumor formation, as previously described (23). MNU was purchased by the NCI Chemical Carcinogen Reference Standards Repository operated under contract by Midwest Research Institute (N02-CB-07008). From 10 to 18 weeks of age, rats were ranked by their rate of weight gain in response to the HF diet. Rats in the top and bottom tertiles of weight gain were classified as obesity-prone (OP) and obesity-resistant (OR), respectively, and matured to produce obese and relatively lean animals. Rats from the middle tertile were removed from the study. Rats were palpated weekly throughout the study to detect tumors, and tumors were measured in 3 dimensions using digital calipers. Fourteen lean and 16 obese tumor-bearing animals entered the OVX phase of the study based on tumor burden. Rats were ovariectomized under isoflurane anesthesia and allowed 4 to 6 days to recover. At OVX, mammary tumor biopsies were obtained via fine-needle aspiration (FNA). Body weight and food intake were monitored weekly before surgery and daily thereafter (18, 22). Body composition was determined at OVX and at sacrifice by quantitative magnetic resonance (qMRI; Echo MRI Whole-Body Composition Analyzer). Metabolic monitoring system During surgical recovery, animals were placed in a metabolic monitoring system (Columbus Instruments) for the remainder of the study. This system includes a multichamber indirect calorimeter to estimate energy intake, total energy expenditure, and fuel use from measurement of oxygen consumption (vO2), carbon dioxide production (vCO2), and urinary nitrogen (10, 18, 22). We have previously reported a 3-week period of rapid weight gain following OVX (22, 23). To ensure our nutrient tracer study was conducted during this weight gain period, but before weight gain plateaued, the tracer study was conducted 10.5 0.7 days after surgical recovery. Dual-tracer protocol During the final 24 hours of the study, a dual-tracer approach was used to monitor the trafficking of glucose and dietary fats in each animal (10, 24, 25). A 1-C-oleate/ 1-C palmitate tracer was blended with the HF diet to achieve a specific activity of 0.52 mCi/kcal of dietary lipid. Animals had ad libitum access to this diet during the 24-hour monitoring period and up to the time of sacrifice. Two hours before completion of the study period, each animal received an intraperitoneal injection of H-2-deoxyglucose (H-2DOG, 100 mCi) to measure tissue-specific glucose uptake. C and H content of individual tissues was determined as previously described (10, 24, 25). Low and high energy excess groups To dissect the individual contributions of obesity and excess energy to our outcome measurements, the lean and obese groups were subclassified by mean energy imbalance (intake minus expenditure) during the window of rapid weight gain. Subclassification was based on each animal's average energy balance during the 48-hour period before sacrifice (Fig. 1A and B) and were termed low (9.3 kcal/day excess; n 1⁄4 7 lean and 7 obese) and high (26.7 kcal/day excess; n 1⁄4 7 lean and 9 obese) energy excess. Plasma and urine measurements Tail vein blood was collected on the second diestrus day of the estrous cycle (22) during the week before OVX, and after OVX at sacrifice. All blood draws were made during the latter part of the light cycle, and plasma was isolated and stored at 80 C. Plasma 17b-estradiol wasmeasured by ELISA (Cayman Chemical). Insulin, leptin, amylin, and glucagon were simultaneously measured using the Rat Endocrine LINCOplex Assay (RENDO-85K; Millipore). Colorimetric assays were used to measure free fatty acids (Wako Chemicals), glucose, triglycerides, and total cholesterol (#TR15421, TR22321, and TR13521, respectively; Thermo-Fisher). Urinary nitrogen was estimated from measurements of urea and creatinine in 24-hour urine coll